A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma

Studies demonstrate that GRM, expressed by >60% of human melanomas, may be a therapeutic target. We performed a phase II trial of 100 mg po bid of riluzole, an inhibitor of GRM1 signaling, in patients with advanced melanoma with the primary endpoint of response rate. Thirteen patients with GRM1-p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pigment Cell Melanoma Res
Main Authors: Mehnert, Janice M., Silk, Ann W., Lee, J. H., Dudek, Liesel, Jeong, Byeong-Seon, Li, Jiadong, Schenkel, Jason M., Sadimin, Evita, Kane, Michael, Lin, Hongxia, Shih, Weichung J., Zloza, Andrew, Chen, Suzie, Goydos, James. S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6013351/
https://ncbi.nlm.nih.gov/pubmed/29453787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12694
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados